Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$4.39 - $5.43 $118,881 - $147,044
27,080 New
27,080 $121,000
Q4 2020

Feb 26, 2021

SELL
$35.35 - $50.67 $855,081 - $1.23 Million
-24,189 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$35.98 - $47.66 $644,905 - $854,257
17,924 Added 286.1%
24,189 $1.73 Million
Q3 2020

Nov 12, 2020

SELL
$35.98 - $47.66 $748,923 - $992,042
-20,815 Reduced 76.86%
6,265 $231,000
Q2 2020

Aug 18, 2020

BUY
$45.06 - $67.74 $130,268 - $195,836
2,891 Added 11.95%
27,080 $1.22 Million
Q4 2019

Feb 11, 2020

BUY
$37.13 - $74.62 $117,145 - $235,426
3,155 Added 15.0%
24,189 $1.73 Million
Q3 2019

Nov 15, 2019

SELL
$39.36 - $76.8 $79,546 - $155,212
-2,021 Reduced 8.77%
21,034 $828,000
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $417,331 - $650,122
7,910 Added 52.23%
23,055 $1.8 Million
Q1 2019

May 14, 2019

BUY
$27.39 - $68.41 $148,590 - $371,124
5,425 Added 55.81%
15,145 $903,000
Q4 2018

Feb 13, 2019

BUY
$22.8 - $33.93 $221,616 - $329,799
9,720 New
9,720 $280,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Doheny Asset Management /Ca Portfolio

Follow Doheny Asset Management /Ca and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

News

Stay updated on Doheny Asset Management /Ca with notifications on news.